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1051-192 Prevention of Renal Function Worsening After Coronary 
Angioplasty: The Role of Acetylcysteine 
Claude Le Feuvre, Rachid El Mahmoud. GBrard Helft, Farzin Beygui, Jean P. Batisse, 
Jean P. Metzger, lnstitut de Cardiologie, Groupe Hospitalier Piti&Salp&tri&e, Paris, 
FranCa 
Recent studies have suggested that oral administration of acetylcysteine could prevent 
the reduction in renal function induced by radiographic contrast agents in patients with 
chronic renal failure. Our prospective, controlled, open-label study included 100 consec- 
utive patients with baseline serum creatinine > 1.5 mg/dl and intravenous hydratation 
who underwent coronary angiography. Baseline and peak post-procedure serum creati- 
nine levels during the following 46 hours were compared in 50 patients with acetylcys- 
teine (600 mg bid, before and after administration of the contrast agent) and 50 patients 
without acetylcysteine. The baseline clinical characteristics, creatinine levels (Z.l+/-1.2 
YS 1 .a+/-0.4 mgldl) and constrast volume (171+/-72 vs 162+/-63 ml) of the 2 groups were 
similar. The mean changes in creatinine after 24 and 46 hours were -O.l+/-0.2 and O+/- 
0.3 mgldl in the acetylcysteine group vs O+/-0.2 and 0~1-0.4 mgidl in the control group 
(NS). A contrast-agent-induced renal dysfunctioq, defined as 25% increase in creatinine 
levels, occurred in 2 patients of the acetylcysteine group and 2 patients of the control 
group. 
Conclusions : A contrast-agent-induced renal dysfunction is rare in patients with intrave- 
nous hydratation and low volumes of contrast-agent. Our study does not confirm the pro- 
phylactic effect of acetylcysteine in the prevention of contrast-agent-induced reduction in 
renal function after coronary angiography. 
1051-193 Do the Ethnic Differences in Presentation and 
Treatment Strategy Influence Outcomes of 
Contemporary Percutaneous Coronary Intervention? A 
Report From the National Heart, Lung, and Blood 
Institute Dynamic Registry 
James Slater, Faith Seizer, Sharmila Dorbala, Deborah Tormey, Helen A. Vlachos, 
Robert L. Wilenskv. Alice K. Jacobs. John S. Doualas. Jr.. Shervl F. Kelsev. St. Luke’s- 
Roosevelt Medica; Center, New York, NY, University of Pittsburgh, Pittsburgh, PA 
BackgroundlMethods: Information about the Impact of racelethnicity on outcomes fol- 
lowing percutaneOus coronary interventions (PCI) in the modern era is limited. We inves- 
tigated differences in clinical presentation, treatment strategy, and acute and l-year 
outcomes between consecutive patients from different ethnic backgrounds (3669 white, 
446 black, 301 Hispanic and 201 Asian) undergoing PCI between 1997 and 1999. The 
NHLBI Dynamic Registry was established to characterize contemporary PCI practice and 
was designed to incorporate an enriched sample of ethnic minorities. All statistical com- 
parisons were made to whites. 
Results: Other than mean age (63.5 years white vs 58.7 years black, 61.1 years His- 
panic, 61.6 years Asian, all p<O.O5). non-whites presented with a higher prevalence of 
the cardiovascular disease risk factors hypertension (58% white vs 79% black, 69% His- 
panic, 69% Asian, all p.zO.01) and diabetes (25% white vs 41% black, 45% Hispanic, 
34% Asian; all ~~0.01). Unstable angina was common in all groups although blacks were 
more likely to present with an acute Ml (29.4% vs 21.4%, p<O.OOl). Extent of vessel dis- 
ease was similar to whites. While the rate of stent implantation was lower in blacks (63% 
vs 74%. p<O.O01), angiographic and procedural success rates were high (r95%) and did 
not differ by race/ethnicity. In-hospital mortality was lower in blacks (0.2% vs 1.7%, 
pcO.O5), however after adjustment for important baseline factors, the risk of in-hospital 
mortality between blacks and whites was attenuated and not different (OR 0.13; 95% Cl 
0.02-1.09). In-hospital death/Ml rates were similar (4.3% white, 2.7% black, 2.7% His- 
panic, 5.0% Asian). At l-year, cumulative death (5.2% white, 4.0% black, 6.3% Hispanic, 
7.6% Asian) and repeat PCliCABG (19.3% white, 18.7% black, 14.5% Hispanic, 22.5% 
Asian) rates among the minority/ethnic groups did not differ from whites. 
Conclusions: Considerable differences in patient demographics, clinical presentation, 
angiographic characteristics and treatment strategies by ethnic minority groups existed. 
Despite these differences, the incidence of acute complications and one-year adverse 
outcomes among minority groups was similar to whites. 
1051-194 Angioplasty Versus Coronary Artery Bypass Surgery in 
Patients With Chronic Kidney Disease 
Gurudutt B. Kulkarni, John A. House, Gregory Muehlebach, Steven P. Marso, Mid 
America Heart Institute, Kansas City, MO, Saint Luke’s Hospital, Kansas City, MO 
Background: Patients with chronic kidney disease (CKD) are at increased risk of death 
following PCI or CABG. There is limited data comparing these two strategies in patients 
with CKD. Methods: We analyzed the PCI and CABG registries. CKD was categorized 
by creatinine clearance (&Cl) into stagesl(CrCI >90ml/min), 2 (60~89ml/min),3(30-59mll 
min), 4(15-29mllmin) and 5(<15ml/min or on hemodialysis). Patients included in the PCI 
cohort had at least 2 vessel coronary artery disease (CAD) with the involvement of Left 
Anterior Descending artery. Patients with left main CAD,prior CABG or PCI were 
excluded. Using the following variables-age,gender,diabetes, LV function, number of dis- 
eased vessels, hypertension, congestive heart failure, acute myocardial infarction or 
unstable angina, we developed a propensity score to calculate the probability of under- 
going PCI. Logistic regression analysis with propensity score adjustment was done to 
assess the impact of CKD on lyear mortality. Results: 2,117 patients in PCI and 1,466 
patients I” CABG coholt were studied. The CABG group was younger, more likely dia- 
betic, had decreased LV function, and unstable angina. No difference in number of dis- 
eased vessels and congestive heart failure. By multivariate logistic regression analysis 
there was no difference in l-year mortality between PCI and CABG cohorts in all stages 
of CKD (see table). 
CKD stage(Number of patients) 
Stage 5(25) 
4(190) 
3(1453) 
2(1302) 
l(427) 
OR for death (95% Cl) 
P=NS 
PCI versus CABG 
0.9(0.04-l 9) 
2.1(0.8-5.3) 
1.0(0.6-l .6) 
1.3(0.6-2.6) 
7.9(0.6-74) 
Conclusion: There was not an increased hazard of mortality with increasing CKD stages 
for patients undergoing PCI compared with CABG. 
1051-195 Prevention of Rheolytic Thrombectomy Induced 
Bradyarrhythmias With Aminophylline 
Brendan M. Browne, Alan S. Brenner, Douglas Ebersole, Lazaro Diaz. Robert Martinez, 
Kenneth Bulman, Kevin F. Browne, Watson Clinic, Lakeland, FL 
Background: Previous studies have shown that rheolytic thrombectomy results in ade- 
nosine release by hemofyzed red blood cells. Adenosine is the proposed agent that 
causes bradycardia and asystole known to be associated with rheolytic thrombectomy. 
Aminophylline has been shown to block adenosine receptors in cardiac tissue. This retro- 
spective study evaluated whether administration of aminophylline prior to rheolytic throm- 
be&my prevented bradycardia. 
Methods: The study group consisted of 39 patients presenting with an acute coronary 
syndrome who were divided into a non-aminophylline group (18 patients) and an amino- 
phylline group (21 patients). Records were reviewed for the frequency of treatment for 
hemodynamically significant bradycardia. 
Results: Of the 18 patients in the non-aminophylline group. temporary pacemakers were 
prophylactically placed in 11 (61%). Of the other 7 patients, 3 patients required treatment 
with &opine. In 21 patients receiving aminophylline. 15 (72%) experienced no dysrhyth- 
miss, 3 (14%) experienced bradycardia not requiring treatment and 3 (14%) experienced 
bradycardia requiring atropine. Of all 39 patients, 37 were procedural wccesses by TIMI 
definition (Grade 3 perfusion). one had TIMI 2 flow and only one was left with TIMI 0 flow. 
Therefore, 14/l 8 non-aminophylline compared with 3/21 aminophylline treated patients 
received treatment for bradycardia. 
Conclusion: Aminophylline appears to obviate the need for a prophylactic temporaly 
pacemaker and may become the preferred primary method for prevention of bradycarda 
during rheolytic thrombectomy. 
1051-196 Triple Antiplatelet Therapy Does Not Increase Femoral 
Access Bleeding With Vascular Closure Devices: 
Results From TARGET 
Jose E. Exaire, Harold L. Dauerman, David J. Molitemo, James C. Blankenship, Amy 
Hsu, Russell E. Raymond, Eric R. Powers, Eric A. Cohen, Eric J. Topol, The Cleveland 
Clinic Foundation, Cleveland, OH, University of Vermont, Burlington, VT 
Background: The use of closure devices (CD) to achieve hemostasis after femoral 
artery access in PCI is steadily increasing. However, the safety information with these 
devices in the era of triple antipfatelet therapy is limited. We reviewed the prospectively 
collected data from the TARGET trial, being the largest such PCI dataset using concomi- 
tant ASA, clopidogrel and Ilb/llla therapy. 
Methods: Patients randomly received abciximab or tirofiban, along with pre-procedural 
aspirin and clopidogrel loading. All patients received heparin aiming for an ACT of _> 250 
seconds. At the treating physician’s discretion, manual compression (MC) or vascular 
device hemostasis was selected following femoral angiography. Patients receiving MC 
were to have sheaths removed 2-6 hours post-procedure when the ACT was i 175s or 
aPTT < 50s. 
Results: Of TARGET’s 4809 patients, 4736 had femoral access, and 985 of these had a 
CD (Perclose 46.8%, Angioseal 43.5%, VasoSeal 4.7%, other 5.0%). The two groups 
were similar regarding most demographic characteristics including age, SBP and weight, 
but those with MC were more often female, diabetic, and had history of PVD. Patients 
with CD had a lower ischemic event rate suggesting they were a lower risk cohorl overall. 
Importantly, there were no differences in major bleeding, minor bleeding or transfusions 
(Table). 
CD (n=985) MC(n=3747) P 
30 day Death, MI, TVR n (%) 44 (4.5) 275 (7.4) 0.002 
Minor bleeding n (%) 42 (4.3) 126 (3.4) 0.174 
Major bleeding n (%) 6 (0.6) 33 (0.9) 0.402 
Transfusions n (%) 11 (1.1) 60 (1.6) 0.266 
Conclusion: In contemporary PCI practice, with appropriate patient selection, CD Can 
be safely utilized despite aggressive polypharmacy for procedural anticoagulation. 
